Cefmenoxime hydrochloride
Based on 1 Customer Validation
Cefmenoxime (SCE-1365) hydrochloride is a new semisynthetic cephalosporin antibiotic. Cefmenoxime has antibacterial activity against a wide variety of gram-positive and gram-negative bacteria.
For research use only. We do not sell to patients.
- Purity : 99.29%
- CAS No.: 75738-58-8
- Formula: C16H17.5Cl0.5N9O5S3
- Molecular Weight:529.79
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
All Antibiotic Isoforms
More
Biological Activity
Description
IC50 & Target
|
β-lactam |
In Vitro
Cefmenoxime (SCE-1365) hydrochloride inhibits at least 90% of strains tested (MIC90) ranged from 0.06 to 8 μg/mL for the Enterobacteriaceae[1].
Cefmenoxime (SCE-1365) hydrochloride inhibits MIC90 values for gram-positive cocci are 0.015 and ≤0.008 μg/mL for Streptococcus pneumoniae and Streptococcus pyogenes, respectively, and 2 μg/mL for S. aureus[1].
Cefmenoxime (SCE-1365) hydrochloride against Haemophilus influenzae, Neisseria gonorrhoeae, and Neisseria meningitidis with MIC90 values ranging from ≤0.008 to 0.25 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Jcl:ICR mice[2]
-
Dosage:40 mg/kg
-
Administration:Subcutaneous injection; daily, for 7 days
-
Result:Inhibited mortality rate of animals was 60% at a dose of 40 mg/kg.
Chemical Information
-
CAS No. 75738-58-8
-
Appearance Solid
-
Molecular Weight 529.79
-
Formula C16H17.5Cl0.5N9O5S3
-
Color White to yellow
-
SMILES
O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O.[0.5HCl]
-
Synonyms
SCE-1365 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
DMSO : 65 mg/mL (122.69 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Stamm JM, et, al. Antimicrobial activity of cefmenoxime (SCE-1365). Antimicrob Agents Chemother. 1981 Mar;19(3):454-60. [Content Brief]
[2]. Tatara O, et, al. Synergistic effects of romurtide and cefmenoxime against experimental Klebsiella pneumonia in mice. Antimicrob Agents Chemother. 1992 Jan;36(1):167-71. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8875 mL | 9.4377 mL | 18.8754 mL | 47.1885 mL |
| 5 mM | 0.3775 mL | 1.8875 mL | 3.7751 mL | 9.4377 mL | |
| 10 mM | 0.1888 mL | 0.9438 mL | 1.8875 mL | 4.7189 mL | |
| 15 mM | 0.1258 mL | 0.6292 mL | 1.2584 mL | 3.1459 mL | |
| 20 mM | 0.0944 mL | 0.4719 mL | 0.9438 mL | 2.3594 mL | |
| 25 mM | 0.0755 mL | 0.3775 mL | 0.7550 mL | 1.8875 mL | |
| 30 mM | 0.0629 mL | 0.3146 mL | 0.6292 mL | 1.5730 mL | |
| 40 mM | 0.0472 mL | 0.2359 mL | 0.4719 mL | 1.1797 mL | |
| 50 mM | 0.0378 mL | 0.1888 mL | 0.3775 mL | 0.9438 mL | |
| 60 mM | 0.0315 mL | 0.1573 mL | 0.3146 mL | 0.7865 mL | |
| 80 mM | 0.0236 mL | 0.1180 mL | 0.2359 mL | 0.5899 mL | |
| 100 mM | 0.0189 mL | 0.0944 mL | 0.1888 mL | 0.4719 mL |